BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Business

  HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancers

  Clinical collaboration to assess HB-200 in combination with KEYTRUDA ® (pembrolizumab) as first-line treatment HOOKIPA poised to advance clinical development program with randomized Phase 2 study in 2022

  September 15, 2021

   · 

  7 min read
• Drug Development

  Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2021

  Landos Biopharma, Inc. (NASDAQ: LABP), today announced that it will present preclinical data of LABP-104, an oral, small-molecule LANCL2 agonist, in Systemic Lupus Erythematosus (SLE or Lupus) as an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2021.

  September 15, 2021

   · 

  7 min read
• Business

  Neurolens Names Pierre Bertrand Chief Executive Officer

  Neurolens announced today that its Board of Directors has appointed Pierre Bertrand as Chief Executive Officer.

  September 15, 2021

   · 

  2 min read
• Drug Development

  Actinium Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B

  Actinium Pharmaceuticals, Inc. today announced that it has completed enrollment of the pivotal Phase 3 SIERRA trial for Iomab-B.

  September 15, 2021

   · 

  13 min read
• Biotech Bay

  Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform

  Allay Therapeutics today announced the completion of its oversubscribed $60M Series C financing, led by Arboretum Ventures.

  September 15, 2021

   · 

  3 min read
• Deals

  Flywheel and Radiologics Join Forces to Create a Truly Unique Global Network for Biomedical Research and Collaboration

  Flywheel, the leading biomedical research data management platform, today announces the acquisition of St. Louis-based Radiologics.

  September 15, 2021

   · 

  4 min read
• Drug Development

  SAB Biotherapeutics Announces Completion of Enrollment in Phase 2a Challenge Trial of SAB-176 for the Treatment of Seasonal Influenza

  SAB Biotherapeutics today announced the completion of enrollment in its Phase 2a clinical trial evaluating the safety and efficacy of SAB-176 in a challenge study.

  September 15, 2021

   · 

  8 min read
• Drug Development

  GammaDelta Therapeutics Initiates First-in-Human Phase 1 Trial of GDX012 for the Treatment of Acute Myeloid Leukaemia

  GammaDelta Therapeutics Ltd. today announced that it has initiated a first-in-human Phase I clinical trial evaluating GDX012 for the treatment of acute myeloid leukaemia (AML)

  September 15, 2021

   · 

  3 min read
• ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021

  ProMIS Neurosciences, Inc. announced today its participation in the Second Annual Undruggable Leaders Forum, a virtual event to be held on September 15-16.

  September 15, 2021

   · 

  3 min read
• Drug Development

  Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)

  Biogen Inc. (Nasdaq: BIIB) today announced plans to initiate a global Phase 3b clinical study, ASCEND.

  September 15, 2021

   · 

  11 min read